Although about 60% of all ovarian tumors display high expression of estrogen receptors (ER) [37], features shared between high-grade serous ovarian cancer and basal-like breast cancer (the majority of which are “triple negative”, i.e. lack expression of estrogen and progesterone receptors and HER2 amplification) have recently been reported. This evidence concerns the gene ERBB2 and ovarian serous adenocarcinoma.